FULGENT GENETICS, INC. Deferred Tax Assets, Equity Method Investments
FULGENT GENETICS, INC. (FLGT) had Deferred Tax Assets, Equity Method Investments of $5.48 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsEquityMethodInvestments · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Equity Method Investments $5.48M.
- 2024-12-31: Deferred Tax Assets, Equity Method Investments $2.96M.
- 2023-12-31: Deferred Tax Assets, Equity Method Investments $503.00K.
- 2022-12-31: Deferred Tax Assets, Equity Method Investments $503.00K.
| Period end | Deferred Tax Assets, Equity Method Investments |
|---|---|
| 2025-12-31 | $5.48M 10-K · filed 2026-02-27 |
| 2024-12-31 | $2.96M 10-K · filed 2026-02-27 |
| 2023-12-31 | $503.00K 10-K · filed 2025-02-28 |
| 2022-12-31 | $503.00K 10-K · filed 2024-02-28 |
| 2021-12-31 | $700.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $700.00K 10-K · filed 2022-02-28 |
| 2017-12-31 | $118.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |